Sales of Zecuity Migraine Skin Patches Halted

Share this content:
Sales of Zecuity Migraine Skin Patches Halted
Sales of Zecuity Migraine Skin Patches Halted

TUESDAY, June 14, 2016 (HealthDay News) -- Sales of the migraine treatment skin patch Zecuity (sumatriptan iontophoretic transdermal system) have been halted after patients reported suffering burns and scars where the patches were applied, Teva Pharmaceutical says.

The Israel-based company also said consumers with the disposable battery-powered patches should stop using them, the Associated Press reported.

The patch is designed to deliver a dose of medicine via a single-use, battery-powered patch that is wrapped around the upper arm or thigh. But some users have developed severe redness, skin discoloration, cracked skin, and pain where patches were applied, according to the U.S. Food and Drug Administration.

Teva said it is recalling the patches and working with the FDA to determine the cause of the skin reactions, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cognitive Training Can Positively Affect Perception of Tinnitus

Cognitive Training Can Positively Affect Perception of Tinnitus

Researchers find computer-based program allows patients to cope better with tinnitus

Early Study Results Promising for Genital Herpes Vaccine

Early Study Results Promising for Genital Herpes Vaccine

Two-pronged approach tested on lab monkeys, guinea pigs

Type 1 Diabetes Tied to Gut Inflammation, Microbiota

Type 1 Diabetes Tied to Gut Inflammation, Microbiota

Type 1 diabetes patients exhibit different and distinct inflammation and gut microbiota

is free, fast, and customized just for you!

Already a member?

Sign In Now »